Virax Biolabs Group Limited Overview
Pro stress-test →Virax Biolabs Group Limited is a biotechnology company that distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company is developing ViraxImmune, an immunology profiling platform that assesses each individual's immune risk profile against global viral diseases and helps with early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation.
Strategic Profile
Pro stress-test →The company has outlined a focused plan centered on advancing ViraxImmune for post-acute infection syndromes (PAIS) and pursuing a U.S. Laboratory Developed Test (LDT) market-entry pathway. Virax achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system (February 2026), supporting regulated IVD development readiness and U.S. clinical validation of ViraxImmune.
Competitive Landscape
Pro stress-test →Virax competes in the immunodiagnostics and viral disease diagnostics space against larger established diagnostics companies. The company differentiates through its T cell-focused ViraxImmune platform targeting post-acute infection syndromes, particularly Long COVID, which remains an underserved market. Competitors include traditional diagnostics providers offering COVID-19 and other viral tests, as well as emerging immunodiagnostics specialists.
Industry Context
Virax Biolabs Group Limited operates in In vitro immunodiagnostics and post-acute infection syndrome testing.
Key facts
Founded: 2022 · Headquarters: Glasgow, United Kingdom · Employees: Unknown · Revenue: Not disclosed · Market cap: ~$2.6M